Abstract 442P
Background
The number of permanent colostomies performed for rectal cancer is decreasing as trans-anal excision has become the first-choice surgical approach. However, the types of support required for patients who undergo permanent colostomies according to their courses are not elucidated. This study aims to identify the types of support needed by elderly permanent colostomy patients by the postoperative months and investigated how these affected their quality of life.
Methods
This study was performed by a hypothesis testing approach using an anonymous self-administered questionnaire, which were left with the participants, and 335 members of A Ostomy Association were recruited to participate. The questionnaire had three components: 11 original items about care needed by individuals with colostomies, the Ostomate QOL Survey and the SF-12v2. Basic respondent characteristics were totaled by simple tabulation, and correlation and multiple regression analyses were performed to investigate how the number of postoperative months affected the support that the individuals with permanent colostomies wished for, and how the support they wished for affected QOL. The survey period was September 2017. This study was approved by the research ethics committee of the institution.
Results
Data from 137 participants of the mean age of 76.5 years were included in the analysis. The analysis on how support individuals felt needed with permanent colostomies affected their QOL resulted in significant correlations between “Factors related to daily life” , “Physical condition” (β=-.294, p=.011), “Activity” (β=-.267, p=.011) and “Mental and emotional condition” (β=-.410, p=.000). The multiple regression analysis on the support that individuals with permanent colostomies wanted and health-related QOL resulted in significant associations between “Factors related to daily life” and “Roles in daily life ((β=-.285, p=.014) ,(β=-.363, p=.001).
Conclusions
This study suggested that there were differences in the support that elderly with permanent colostomies wanted depending on the number of months or years passed since their colostomy surgery. Furthermore, it showed that the more they wished for care related to their daily life and health-related QOL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
JAPS Grant-in-Aid for Scientific Research(B):25293443.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract